Penumbra reports six pulmonary embolism recovery analyses
Penumbra reports six TCT 2026 analyses examining right heart function, symptoms and recovery after pulmonary embolism treatment.

Penumbra reported on November 18, 2026, that it had presented six STORM-PE and STRIKE-PE analyses at TCT 2026 examining recovery after pulmonary embolism treatment. The reported STORM-PE analysis compared early physiological changes and 90-day functional outcomes with computer-assisted vacuum thrombectomy plus anticoagulation against anticoagulation alone.
Six analyses examine pulmonary embolism recovery
The abstracts examine right ventricular recovery, right ventricular–pulmonary artery coupling, functional capacity, symptoms and activity recorded through wearable technology, according to Penumbra’s report. The company positions the research as an examination of recovery in the weeks and months after acute treatment, rather than procedural performance alone.
STORM-PE is a randomized controlled trial, while STRIKE-PE forms another part of Penumbra’s clinical evidence for mechanical thrombectomy in pulmonary embolism. The recovery measures extend the assessment from right heart function to functional capacity, breathlessness and everyday activity.
STORM-PE compares early and 90-day outcomes
The reported STORM-PE number-needed-to-treat analysis involved 100 patients with intermediate-high-risk pulmonary embolism. It compared computer-assisted vacuum thrombectomy plus anticoagulation with anticoagulation alone, providing an active-treatment benchmark for the additional intervention.
Penumbra reported the following results:
- At 48 hours, 78.3% of thrombectomy patients achieved a reduction greater than 0.2 in the right ventricular/left ventricular ratio, compared with 51.9% receiving anticoagulation alone. The reported number needed to treat was 4.
- Across select early physiological parameters or 90-day functional outcomes, the reported number needed to treat ranged from three to five for one additional patient to achieve improvement.
The analysis therefore places early physiological improvement alongside a later functional outcome within the same randomized treatment comparison. That connection is more relevant to recovery assessment than an account limited to the immediate procedure, although it does not establish that early improvement caused the later functional result.
What it means
For Penumbra and competing pulmonary embolism thrombectomy developers, the evidence question extends beyond acute intervention: what additional recovery benefit does the device deliver over anticoagulation alone, and does that benefit persist through 90 days?
For clinical teams evaluating these technologies, the reported results make both 48-hour physiology and 90-day functional status relevant assessment points. The practical distinction is between demonstrating an early treatment effect and demonstrating subsequent recovery. Comparative safety and the precision of the number-needed-to-treat estimates remain necessary considerations before these efficacy findings can support a broader benefit–risk judgment.